XML 64 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2023202220232022
Medicare37 %62 %35 %37 %
Medicare Advantage15 %12 %17 %15 %

Accounts Receivable, Net
 September 30, 2023December 31, 2022
Medicare65 %21 %
Medicare Advantage*13 %
*Less than 10%.
Schedule of Disaggregation of Revenue The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Revenue:
Commercial$6,090 $3,216 $17,789 $14,259 
Government4,955 9,228 13,570 12,242 
Client(1)2,319 2,046 6,999 5,496 
Other(2)52 236 425 729 
Total revenue$13,416 $14,726 $38,783 $32,726 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Schedule of Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 September 30, 2023December 31, 2022
Cash and cash equivalents$28,448 $62,391 
Restricted cash200 200 
$28,648 $62,591 
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 September 30, 2023December 31, 2022
Cash and cash equivalents$28,448 $62,391 
Restricted cash200 200 
$28,648 $62,591 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):
 
 September 30, 2023September 30, 2022
Warrants to purchase common stock409,108 409,108 
Common stock options1,004,855 1,820,555 
Restricted stock units1,568,112 805,496 
Employee stock purchase plan12,542 17,204 
Total2,994,617 3,052,363